TRCT
DERM icon

Tower Research Capital (TRC)’s Journey Medical DERM Stock Holding History

Tower Research Capital (TRC)’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.5K Buy
4,584
+2,115
+86% +$16.4K ﹤0.01% 3435
2025
Q4 		$19K Buy
2,469
+743
+43% +$5.83K ﹤0.01% 3133
2025
Q3 		$12.3K Buy
1,726
+1,635
+1,797% +$11.9K ﹤0.01% 3796
2025
Q2 		$653 Buy
+91
New +$629 ﹤0.01% 4969
2025
Q1 		– Sell
-2,923
Closed -$11.4K – 5298
2024
Q4 		$11.4K Buy
2,923
+2,162
+284% +$11.8K ﹤0.01% 3716
2024
Q3 		$4.3K Sell
761
-4,172
-85% -$21.5K ﹤0.01% 4596
2024
Q2 		$27.8K Sell
4,933
-105
-2% -$432 ﹤0.01% 3545
2024
Q1 		$18.5K Buy
+5,038
New +$21.9K ﹤0.01% 3067
2023
Q4 		– Sell
-1,730
Closed -$4.74K – 5963
2023
Q3 		$4.74K Sell
1,730
-2,352
-58% -$5.25K ﹤0.01% 4820
2023
Q2 		$6.49K Sell
4,082
-1,337
-25% -$2.15K ﹤0.01% 4697
2023
Q1 		$9K Sell
5,419
-2,214
-29% -$4.13K ﹤0.01% 4475
2022
Q4 		$15K Buy
7,633
+2,577
+51% +$5.1K ﹤0.01% 3408
2022
Q3 		$12K Buy
5,056
+3,021
+148% +$10.3K ﹤0.01% 4328
2022
Q2 		$8K Sell
2,035
-119
-6% -$471 ﹤0.01% 4668
2022
Q1 		$10K Buy
2,154
+1,498
+228% +$7.48K ﹤0.01% 4296
2021
Q4 		$4K Buy
+656
New +$4.75K ﹤0.01% 5292

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tower Research Capital (TRC)'s DERM Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Journey Medical (DERM) stake by 86% in Q1 2026, buying an estimated $16.4K and bringing the position to 4,584 shares worth $21.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3435.

Tower Research Capital (TRC) first reported a position in DERM in Q4 2021 and has held it in 16 quarters since. The position peaked at $27.8K in Q2 2024. 71 funds tracked by Wall St. Rank hold DERM as of Q1 2026.

  • Tower Research Capital (TRC) held 4,584 shares of Journey Medical worth $21.5K as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,115 Journey Medical shares in Q1 2026, an estimated $16.4K.
  • Journey Medical made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3435 holding.
  • Tower Research Capital (TRC) first reported a position in Journey Medical in Q4 2021 and has held it in 16 quarters since.
  • Tower Research Capital (TRC)'s Journey Medical position peaked at $27.8K in Q2 2024.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.